Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Lifted by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 25.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,357 shares of the medical equipment provider’s stock after acquiring an additional 1,670 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Zimmer Biomet were worth $1,103,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Advisors Asset Management Inc. bought a new stake in Zimmer Biomet during the third quarter valued at $657,000. Graham Capital Management L.P. boosted its holdings in shares of Zimmer Biomet by 275.2% in the 3rd quarter. Graham Capital Management L.P. now owns 5,951 shares of the medical equipment provider’s stock valued at $668,000 after buying an additional 4,365 shares during the period. Public Sector Pension Investment Board grew its position in shares of Zimmer Biomet by 12.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 22,433 shares of the medical equipment provider’s stock valued at $2,517,000 after buying an additional 2,435 shares during the last quarter. Polar Capital Holdings Plc acquired a new stake in Zimmer Biomet during the third quarter worth about $22,496,000. Finally, Deutsche Bank AG lifted its holdings in Zimmer Biomet by 4.7% in the third quarter. Deutsche Bank AG now owns 629,427 shares of the medical equipment provider’s stock worth $70,634,000 after acquiring an additional 28,496 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZBH shares. Oppenheimer upped their target price on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. The Goldman Sachs Group initiated coverage on Zimmer Biomet in a research report on Thursday, May 30th. They issued a “neutral” rating and a $129.00 target price on the stock. Evercore ISI reduced their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating for the company in a report on Tuesday, July 2nd. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Tuesday, May 21st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $131.76.

Zimmer Biomet Price Performance

ZBH traded up $0.46 during trading on Wednesday, reaching $106.22. The stock had a trading volume of 134,726 shares, compared to its average volume of 1,491,806. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $144.13. The firm has a market capitalization of $21.85 billion, a price-to-earnings ratio of 22.88, a price-to-earnings-growth ratio of 1.91 and a beta of 1.01. The stock has a 50 day moving average of $113.31 and a two-hundred day moving average of $120.58. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.89 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.